

## Zambia

### Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Zambia						
<b>2. Vaccine grant number:</b>	12-ZMB-08a-Y, 1215-ZMB-12B-X, 16-ZMB-12b-X, 17-ZMB-12b-X, 18-ZMB-25a-Y, 1821-ZMB-12a-X						
<b>3. Date of Decision Letter:</b>	30 September 2019						
<b>4. Date of the Partnership Framework Agreement:</b>	22 October 2014						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Pneumococcal , Routine						
<b>6. Vaccine type:</b>	Pneumococcal						
<b>7. Requested product presentation and formulation of vaccine:</b>	PCV10, 4 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2012-2021						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2012-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	49,182,359	4,450,000	4,917,000	-	-	-	58,549,359
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2012	12-ZMB-08a-Y					537,268
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	30 January, 2012						207,000
	17 December, 2012						344,500
	04 February, 2016						(14,232)
<b>11. Product switch grant</b>							
	<b>Approval</b>						
	<i>Approval</i>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2018	18-ZMB-25a-Y					204,986
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2012-2019	2020
Number of vaccine doses		1,323,600
Annual Amounts (US\$)	49,182,359	4,450,000

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**  
According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021
Number of vaccine doses	322,800	464,400
Number of AD syringes	319,700	460,000
Number of re-constitution syringes	-	-
Number of safety boxes	3,525	5,075
Value of vaccine doses (US\$)	983,721	1,415,606
Total co-financing payments (US\$) (including freight)	1,006,500	1,449,500

**16. Operational support for campaigns:**  
Not applicable

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
<b>18. Financial clarifications:</b>  Not applicable	
<b>19. Other conditions:</b>  Not applicable	

Signed by,  
**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30 September 2019